Dr. Jayram discusses how patients with UC at high risk of recurrence after radical resection may benefit from adjuvant immunotherapy. He emphasizes the role of multidisciplinary communication in patient care & reviews a subcutaneous immunotherapy option.

A milestone in my career

High prevalence of coexisting pelvic symptomatology is observed in those with pelvic floor disorders, especially in chronic pelvic pain. Read in #ContinenceJournal sciencedirect.com/science/articl… #PelvicHealth #ChronicPain #MultidisciplinaryCare #Urogynecology

Phishing Alert! A fake email is impersonating our CEO, Dominic Turner, asking for help with board matters. ❌ It’s not from ICS — don’t click, reply, or open anything. Report it: Gmail: “More” > “Report phishing” Outlook: “Report” > “Phishing” Then delete it. – ICS Office Team

📢 Out Today: The July Edition of #SIU eNews! Catch up on upcoming society activities: 🔬 Late-Breaking Abstracts & Clinical Trials details and deadlines. There is still time to submit your latest research for #SIU2025Edinburgh! 🎓 New content on #SIUAcademy The next

Risk stratification for active surveillance in low and intermediate-risk #BladderCancer. Marco Moschini Ospedale San Raffaele and Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center discuss expanding active surveillance criteria for recurrent low-grade bladder cancer. #WatchNow > bit.ly/42wshVz

📹 What defines high-risk NMIBC? When is #radicalcystectomy the right move? And how do patient values shape the choice? Watch this roundtable discussion from #UROonco25 with experts Assoc. Prof. Aning, Dr. Mir and Dr. Moschini to learn more 👇 bladder.uroonco.uroweb.org/video/round-ta…

Per la #GiornataNazionaleDellUrologia (17 luglio) i nostri camper della prevenzione SIU faranno tappa in 3 città per offrire consulenze urologiche gratuite, materiale informativo e momenti di divulgazione scientifica destinati ai cittadini, un'importante opportunità per

👨‍⚕️ Nella #GiornataNazionaleDellUrologia, il nostro presidente Giuseppe Carrieri sarà ospite a Tg1 per parlare di prevenzione e benessere urologico. #Urologia

Managing BCG-unresponsive #BladderCancer: Balancing bladder preservation and cystectomy. Paolo Gontero & Maria Carmen Mir, MD, PhD join Ashish M. Kamat, MD, MBBS in a discussion addressing management approaches for BCG-unresponsive bladder cancer. #WatchNow on UroToday >

Exciting News! #ICSEUS2025 in Abu Dhabi has been granted 28.5 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®). ✅ Earn CME credits while advancing your practice. Register: ics.org/2025/register #ContinenceEvent

🎥 Missed our ICS Masterclass? Catch up now on "Shared Decision-Making in LUTS Diagnostics" with Drs. van Balken & Kuang — exploring the patient voice in urodynamics. 📺 Watch on ICS TV: ics.org/masterclass/25… #ICSTV #ICS #Urodynamics #UrodynamicsUnderTheLens

Societie International d'Urologie (SIU) is a urological society with more than 17,000 members from over 130 countries globally. This year, the SIU Congress will be held in Edinburgh from 29th October to 1st November. Registration link: siu-urology.org/congress-2025/…

Great society & Great event Dont miss

Great event & Great society Don't miss

In this systematic review, the authors assess the impact of extended #pelvic #lymphadenectomy vs. standard pelvic lymphadenectomy in #bladder #cancer patients undergoing #radical #cystectomy. 🔗to Full Article: mdpi.com/3347750 📜Latest Issue: mdpi.com/2563-6499/6/3

📣 Join us for the first-ever Patient Awareness Event on Urinary Incontinence in the Middle East! 🗓️ 17 Sept 2025 | 🕐 13:30–17:30 📍 Mediclinic Airport Rd Hospital, Abu Dhabi 🎤 Talks, panels & networking ✅ Free registration: ics.org/calendar/1394 #ICSEUS2025 #Incontinence

Coming soon, welcome to all urologists & freinds

📢 LATE-BREAKING ABSTRACT SUBMISSIONS NOW OPEN! Missed the regular abstract deadline because your research wasn’t quite ready? If your findings just came through, you still have a chance to present at #SIU2025Edinburgh! 🔬 What is a Late-Breaking Abstract? This category is

TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study | Journal of Clinical Oncology ascopubs.org/doi/pdf/10.120…